

Crucell

Crucell at a glance

July 2010

Fast Facts

Headquarters	: Netherlands
Listing	: NYSE Euronext, NASDAQ, SWX
Technology	: PER.C6 [®] , AdVac [®] , MAbstract [®] , STAR [®] , virosomes
Products	: Vaccines and antibody products
Facilities	: Switzerland, Korea, Spain, Sweden, Netherlands
Partners	: Global distribution; broad base of technology licensees
Market Cap	: Approx. €1.2 bln (2 July, 2010)
Holdings	: 6% Galapagos Genomics N.V. (GLPG) 12% AdImmune Corporation (private)

Mission: Combating infectious diseases

Crucell's mission is to protect human lives from infectious diseases by bringing meaningful innovation to global health.

Crucell at a Glance

Crucell is a fully integrated biopharmaceutical company. We focus on developing, producing and marketing products that combat infectious diseases.

We develop products that address currently unmet medical needs, particularly in the field of infectious diseases. We have a fully integrated infrastructure for in-house development, production and marketing of vaccines, and we are leveraging our knowledge in the vaccines field to excel in the antibodies market. Our competitive edge comes from our proprietary technology platforms, like PER.C6[®], which is ideally suited to the high-yield, low-cost manufacture of vaccines and therapeutic proteins, such as antibodies. The markets we operate in, our technological knowledge and our quality marketed products position us to be a major player in the multi-billion dollar biopharmaceutical arena.

In addition to our own research & development activities, we have strategic partnerships with several leading healthcare companies. Through these agreements, our technologies play a vital role in the development of a vast number of vaccine and antibody products. Our strategic partners include Johnson & Johnson, DSM Biologics, Novartis, MedImmune, Merck, sanofi pasteur and Wyeth.

Infectious diseases currently account for a significant number of human casualties throughout the world. The number of infectious outbreaks is increasing for many reasons: higher population density which raises exposure to infectious agents; an ageing population which is more susceptible to infection; and a rise in global travel which boosts the potential for spreading diseases across borders.

Cruce

Research & Development Pipeline

Our research efforts today are focused on developing vaccines and antibodies that address unmet medical needs and infectious diseases. Our research efforts are bolstered by our range of technologies, which play a critical role in our development programs.

Vaccines in development:

Flavimun®		Yellow fever vaccine.
Influenza seasonal (flu cell)		Seasonal influenza vaccine. ¹
Tuberculosis		Recombinant AdVac®-based tuberculosis vaccine. ²
Malaria		Recombinant AdVac®-based malaria vaccine. ³
Ebola and Marburg		Recombinant AdVac®-based Ebola and Marburg vaccine. ³
HIV		Recombinant AdVac®-based vaccine. ⁴

Human monoclonal antibodies in development:

Rabies antibody combination		Two human monoclonal antibodies for post-exposure treatment of rabies. ⁵
Influenza antibodies		Neutralizing antibody cross reactive against different influenza subtypes including H5 and H1.
Hepatitis C antibody combination		Neutralizing monoclonal antibodies across all genotypes tested.

Technologies

Our strong product portfolio is supported by a range of patented, cutting-edge technologies.


PER.C6®	Human cell line for development and large-scale manufacturing
AdVac®	Used in combination with PER.C6® to develop recombinant vaccines
MAbstract®	To discover novel drug targets and identify human monoclonal antibodies
STAR®	To enhance yields of recombinant human antibodies and proteins
Virosome	A vehicle enabling the use of virus antigens in the making of vaccines

Crucell

Products


Our vaccine business provides stable and predictable sales and cash flow. In 2009, we distributed more than 115 million vaccine doses in over 100 countries throughout the world. Within vaccines, we operate in three main franchises: paediatric, travel & endemic, and respiratory.

Paediatric:



Quinvaxem[®] Fully liquid vaccine for protection against five childhood diseases
Hepavax-Gene[®] Recombinant hepatitis B vaccine
MoRu-Viraten[®] Vaccine for protection against measles and rubella (all ages)
Epaxal[®] Junior Low dosage aluminum-free hepatitis A vaccine (0.25 ml)

Travel & Endemic:



Epaxal[®] Aluminum-free hepatitis A vaccine
Vivotif[®] Oral typhoid vaccine
Dukoral[®] Internationally licensed oral vaccine against cholera (and ETEC)

Respiratory:



Inflexal[®] V Virosomal adjuvanted influenza vaccine (all age groups)



Crucell

www.crucell.com